Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia

Blood

Volumn 127, Issue 20, 2016, Pages 2439-2450

  Bellon, Marcia ^a   Lu, Ling ^a   Nicot, Christophe ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; AZD 1208; CDC25A PROTEIN; CYCLIN A; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; CYCLINE B1; CYCLINE E; GELATINASE A; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MICRORNA 124; MICRORNA 124A; MYC PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN FOS; PROTEIN KINASE PIM 1; PROTEIN P53; PROTEIN SERINE THREONINE KINASE INHIBITOR; SMI 4A; STAT3 PROTEIN; SURVIVIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; AZD1208; BIPHENYL DERIVATIVE; MICRORNA; MIRN124 MICRORNA, HUMAN; PIM1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; STAT3 PROTEIN, HUMAN; THIAZOLIDINE DERIVATIVE; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE MUTATION; HTLV-1 INFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; TRANSFORMED CELL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; UPREGULATION; XTT ASSAY; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL ADHESION; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HEK293 CELL LINE; HUMAN T-LYMPHOTROPIC VIRUS 1; MOLECULARLY TARGETED THERAPY; MUTATION; PHYSIOLOGY; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TRANSFORMED CELL LINE;

ANIMALS; APOPTOSIS; BIPHENYL COMPOUNDS; CELL ADHESION; CELL LINE, TRANSFORMED; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, LEUKEMIC; GENE SILENCING; HEK293 CELLS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; MICE; MICRORNAS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM PROTEINS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-PIM-1; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; THIAZOLIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84974721740     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-11-685032     Document Type: Article

References (39)

1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA. 1980;77(12):7415-7419.
2. Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA. 1982;79(6):2031-2035.
3. Mahieux R, Gessain A. HTLV-1 and associated adult T-cell leukemia/lymphoma. Rev Clin Exp Hematol. 2003;7(4):336-361.
4. Marçais A, Suarez F, Sibon D, Frenzel L, Hermine O, Bazarbachi A. Therapeutic options for adult T-cell leukemia/lymphoma. Curr Oncol Rep. 2013;15(5):457-464.
5. Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27(3):453-459.
6. Katsuya H, Ishitsuka K, Utsunomiya A, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126(24):2570-2577.
7. Zhang M, Mathews Griner LA, Ju W, et al. Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia. Proc Natl Acad Sci USA. 2015;112(40):12480-12485.
8. Franchini G. Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection. Blood. 1995;86(10):3619-3639.
9. Migone TS, Lin JX, Cereseto A, et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science. 1995;269(5220):79-81.
10. Quintás-Cardama A, Verstovsek S. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res. 2013;19(8):1933-1940.
11. Massoud R, Enose-Akahata Y, Tagaya Y, Azimi N, Basheer A, Jacobson S. Common g-chain blocking peptide reduces in vitro immune activation markers in HTLV-1-associated myelopathy/tropical spastic paraparesis. Proc Natl Acad Sci USA. 2015;112(35):11030-11035.
12. Ju W, Zhang M, Jiang JK, et al. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood. 2011;117(6):1938-1946.
13. Yamano Y, Takenouchi N, Li HC, et al. Virus-induced dysfunction of CD4+CD25+ T cells in patients with HTLV-I-associated neuroimmunological disease. J Clin Invest. 2005;115(5):1361-1368.
14. Siddiquee K, Zhang S, Guida WC, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA. 2007;104(18):7391-7396.
15. Pancewicz J, Taylor JM, Datta A, et al. Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia. Proc Natl Acad Sci USA. 2010;107(38):16619-16624.
16. Bellon M, Ko NL, Lee MJ, et al. Adult T-cell leukemia cells overexpress Wnt5a and promote osteoclast differentiation. Blood. 2013;121(25):5045-5054.
17. Bellon M, Lepelletier Y, Hermine O, Nicot C. Deregulation of microRNA involved in hematopoiesis and the immune response in HTLV-I adult T-cell leukemia. Blood. 2009;113(20):4914-4917.
18. Li X, Yu Z, Li Y, et al. The tumor suppressor miR-124 inhibits cell proliferation by targeting STAT3 and functions as a prognostic marker for postoperative NSCLC patients. Int J Oncol. 2015;46(2):798-808.
19. Takemoto S, Mulloy JC, Cereseto A, et al. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc Natl Acad Sci USA. 1997;94(25):13897-13902.
20. Saurabh K, Scherzer MT, Shah PP, et al. The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets. Oncotarget. 2014;5(18):8503-8514.
21. Thomas M, Lange-Grünweller K, Weirauch U, et al. The proto-oncogene Pim-1 is a target of miR-33a. Oncogene. 2012;31(7):918-928.
22. Koskela HL, Eldfors S, Ellonen P, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366(20):1905-1913.
23. Kataoka K, Nagata Y, Kitanaka A, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015;47(11):1304-1315.
24. Lin YW, Beharry ZM, Hill EG, et al. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood. 2010;115(4):824-833.
25. Keeton EK, McEachern K, Dillman KS, et al. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 2014;123(6):905-913.
26. Chan JK, Greene WC. Dynamic roles for NF-κB in HTLV-I and HIV-1 retroviral pathogenesis. Immunol Rev. 2012;246(1):286-310.
27. Niitsu Y, Urushizaki Y, Koshida Y, et al. Expression of TGF-beta gene in adult T cell leukemia. Blood. 1988;71(1):263-266.
28. Moles R, Bellon M, Nicot C. STAT1: A Novel Target of miR-150 and miR-223 Is Involved in the Proliferation of HTLV-I-Transformed and ATL Cells. Neoplasia. 2015;17(5):449-462.
29. Yamagishi M, Nakano K, Miyake A, et al. Polycomb-mediated loss of miR-31 activates NIK-dependent NF-κB pathway in adult T cell leukemia and other cancers. Cancer Cell. 2012;21(1):121-135.
30. Moles R, Nicot C. The Emerging Role of miRNAs in HTLV-1 Infection and ATLL Pathogenesis. Viruses. 2015;7(7):4047-4074.
31. Chim CS, Wan TS, Wong KY, Fung TK, Drexler HG, Wong KF. Methylation of miR-34a, miR-34b/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms. J Transl Med. 2011;9:197.
32. Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis. 2010;31(5):766-776.
33. Wong KY, So CC, Loong F, et al. Epigenetic inactivation of the miR-124-1 in haematological malignancies. PLoS One. 2011;6(4):e19027.
34. Cheng Y, Li Y, Nian Y, Liu D, Dai F, Zhang J. STAT3 is involved in miR-124-mediated suppressive effects on esophageal cancer cells. BMC Cancer. 2015;15:306.
35. Jerez A, Clemente MJ, Makishima H, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012;120(15):3048-3057.
36. Eiring AM, Page BD, Kraft IL, et al. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia. 2015;29(3):586-597.
37. Agirre X, Vilas-Zornoza A, Jiménez-Velasco A, et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res. 2009;69(10):4443-4453.
38. Lin TS, Mahajan S, Frank DA. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene. 2000;19(21):2496-2504.
39. Hossain DM, Dos Santos C, Zhang Q, et al. Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. Blood. 2014;123(1):15-25.